Navigation Links
Novavax Announces Repayment of $5 Million of Convertible Debt
Date:7/15/2009

the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the success of the Company's foreign joint venture and licensing agreements; the Company's ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
2. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
3. Novavax Appoints Stanley Erck to Board of Directors
4. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
5. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
6. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
7. Novavax Reports First Quarter 2009 Financial Results
8. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
9. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
10. Novavax Announces Early Retirement of $17 Million of Convertible Debt
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... 2013 Through science fairs, workshops, kits ... lab equipment, 25 organizations will continue their work to ... and photonics in daily life with the aid of ... located in 10 countries, are the first of two ... SPIE, the international society for optics and photonics ...
(Date:5/21/2013)... 2013 Clinverse, Inc. , ... clinical trials, announced today it has formed a ... Clinverse’s ClinPay® FLS eClinical commerce platform aggregates data ... SpendMD ™, Aggregate Spend Solutions’ recently-launched flagship ... and reporting transfer of value at investigator meetings ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Emerson ... announced that Dr. Charles Signorino, the Company’s Chief Executive ... 1, 2013 after 32 years of service. As part ... Emerson’s current President, has been named as Dr. Signorino’s ... in the pharmaceutical industry, having made a significant contribution ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... Quark Pharmaceuticals, Inc.,a development-stage pharmaceutical company ... therapeutics, today announced the,presentation of posters ... taking place,September 16-18, 2008 in Stockholm, ... Hagar Kalinski, and Hagit Ashush, presented ...
... 17 Dendreon Corporation,(Nasdaq: DNDN ) today announced ... of Dendreon, will present a company update at the,UBS ... Monday, September,22, 2008 at 1:30 p.m. ET., A ... through the,Investor Relations section of the Dendreon website, http://www.dendreon.com ...
... China, Sept. 17 /Xinhua-PRNewswire-FirstCall/ --,China Biologic Products, ... the "Company"), one of the leading plasma-based ... ("PRC"), today announced that the Company,received approval ... Administration (the,"SFDA") to commence clinical trial of ...
Cached Biology Technology:Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 2Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008 3China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 2China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII 3
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... Society (ACS), the world,s largest scientific society, invites ... & Exposition, September 8-12, 2013, in Indianapolis, Ind. ... Center and at area hotels. , With more ... science,s horizons from astronomy to zoology ― ... journalists a rich assortment of spot news and ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... of plants genetically tweaked to absorb more contaminants, researchers ... wild-type counterparts. The results raised hopes that the plants ... soil. , The new research findings, published Feb. 1 ... three transgenic lines of the Indian mustard plant, Brassica ...
... of Cell Metabolism has provided insight into a key ... suggests a novel approach to the development of cholesterol-lowering ... of the most prescribed cholesterol inhibitors, according to researchers ... Cells obtain cholesterol, an important component of cell membranes, ...
... Washington Alaska Salmon Program, the world's longest-running effort to ... million from the Gordon and Betty Moore Foundation to ... program has applications for Pacific salmon all along the ... salmon runs and their management. , The grant boosts ...
Cached Biology News:Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 2Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 3Transgenic plants remove more selenium from polluted soil than wild plants, new tests show 4Insight into natural cholesterol control suggests novel cholesterol-lowering therapy 2Alaskan puzzles, monitoring provide insight about North Pacific salmon runs 2
DTT 50 l...
...
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Biology Products: